| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| daclizumab | complement c1q subcomponent subunit a | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | complement c1q subcomponent subunit b | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | complement c1q subcomponent subunit c | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | complement c1r subcomponent | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | high affinity immunoglobulin gamma fc receptor i | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | low affinity immunoglobulin gamma fc region receptor ii-a | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | low affinity immunoglobulin gamma fc region receptor ii-b | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | low affinity immunoglobulin gamma fc region receptor ii-c | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | low affinity immunoglobulin gamma fc region receptor iii-a | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | low affinity immunoglobulin gamma fc region receptor iii-b | biotech | NA | drugbank | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
NA | investigational,withdrawn | unknown |
| daclizumab | interleukin-2 | NA | Successful target | TTD , DGIDB | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
0.5 | approved | unknown |
| daclizumab | interleukin-2 receptor subunit alpha | biotech | NA | drugbank , DGIDB | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
6.04 | investigational,withdrawn | antibody |
| daclizumab | interleukin-2 receptor subunit alpha | biotech | NA | drugbank , DGIDB | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
6.04 | investigational,withdrawn | antibody,inhibitor |
| daclizumab | interleukin-2 receptor subunit beta | biotech | NA | drugbank , DGIDB | Graft Rejection[MeSHID:D006084] Kidney[MeSHID:D007668] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Sclerosis[MeSHID:D009103] |
18.56 | investigational,withdrawn | antibody,inhibitor |
| click here to return to the previous page | ||||||||